Glioma is a primary intracranial malignant tumor originating from glial cells or progenitor cells, accounting for 25.5% of central nervous system tumors. Clinically, the treatment of glioma mainly depends on surgical resection,Read More…
New Breakthrough in Anti-Cancer! PROTAC has Obtained Preclinical Proof of Concept for T-ALL Treatment
Acute lymphoblastic leukemia (ALL) is a common disease. B-ALL and T-ALL account for 85% and 15% of the two lymphatic lineages of ALL, respectively, but patients with T-ALL have poor life qualityRead More…
PROTACs Provide Both Academia and Business a Tremendous Opportunity
In the past 20 years, PROTAC has ushered in a period of rapid development, especially since the successful degradation of BET protein by dBET1 PROTAC with pomalidomide as the ligand of anRead More…
Cell: Novel PROTAC—Can Be Used as A New Antibacterial Agent
Induced degradation of target proteins is a new concept in drug discovery. For eukaryotes, the ubiquitin-proteasome system is the main pathway of intracellular protein degradation, which participates in more than 80% ofRead More…
Newly Discovered: The First Microbial-Derived PROTAC Molecule
PROTAC (Proteolysis-Targeting Chimera) technology, by linking E3 ubiquitin ligase to the target protein, leads to the ubiquitin modification of the target protein, which is broken down into peptides and amino acids byRead More…
Study of PROTAC in Tumor Targeted Therapy-Ⅱ
Targeting tumor cell apoptosis and angiogenesis Apoptosis (or programmed cell death) is an evolutionarily conservative process that maintains tissue homeostasis under cellular stress, DNA damage and immune surveillance. However, cancer cells canRead More…
Study of PROTAC in Tumor Targeted Therapy-Ⅰ
The occurrence and development of cancer is a complex process, which is characterized by continuous proliferation signals, avoidance of growth inhibitors, resistance to cell death, induction of angiogenesis, activation of invasion andRead More…
Review of PROTAC Targeted Degradation of Protein Kinases
PROTAC consists of a flexible linker conjugating the protein of interest (POI) ligand and an E3 ligase ligand. Its action mechanism makes use of the mechanism of protein degradation induced by theRead More…
E3 Ligase, Critical for PROTAC Design
A core factor of PROTAC molecules is that protein degradants can be designed rationally by selecting ligase molecules and linkers according to the target. The module that binds to E3 ligase canRead More…
PROTACs-Induced Protein Degradation ─ A New Model in Drug Discovery
PROTAC Concept PROTACs has become a new model of drug discovery, with the potential to change traditional drug discovery, and may become a new blockbuster therapy. PROTACs is a bifunctional separator, whichRead More…